Evaluation of Intravenous Thrombolytic Therapy in Patients with Acute Ischemic Stroke Presented within Window Period in a Tertiary Care Hospital

Abstract

The use of intravenous recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke (AIS) within 3 hours of onset was approved, and the therapy was later extended to 4.5 hours. The current Ambispective observational study was conducted at Krishna Institute of Medical Sciences (KIMS) in Hyderabad, India, to assess the outcomes of thrombolysis in patients with acute ischemic stroke who presented within the window period in a tertiary care hospital, which may decrease continual neurologic harm, death, and long-term disability. Between 2017 and 2018, AIS patients who received rt-PA 3-4.5 hours after onset in hospitals were included in the therapy group. Patients' names, ages, genders, body weights, lengths of stay, marital status, dietary habits, stroke type, stroke clinical features in hospital, discharge medicines (dosage, frequency), and condition at discharge were all recorded along with their NIHSS scores. There are 40 participants in the research. The current study's findings support the use of rt-PA in ischemic stroke patients within 3-4.5 hours of onset and under clinical monitoring as an effective and acceptable treatment for functional status after stroke.